10x Genomics Shares Hit $68.59 Amid Insider Selling

10x Genomics Inc (TXG) shares closed at $68.59 on September 11, 2026, marking a 3.3% daily increase. This move keeps the stock near its 52-week high of $69.67, reflecting a year-to-date gain of 320.5% and a one-year return of 425.2%. The price action continues a sustained uptrend that has decoupled the market valuation from the company's historical trading multiples.

According to GuruFocus data, the stock now trades at a 273.8% premium to the GF Value™ estimate of $18.35. This valuation gap exists because the company remains unprofitable and cash-flow negative, rendering traditional price-to-earnings metrics inapplicable. Instead, the market is pricing the stock at a significant multiple of sales, far exceeding the historical median P/S ratio of 10.3x.

Valuation gap exceeds historical sales multiples

The current pricing implies that investors are paying a substantial premium for future growth potential rather than current financial results. With a GF Score™ of 56/100, the company displays average overall performance, but the sub-scores reveal a stark contrast. Financial strength is rated 8/10, indicating a robust balance sheet capable of sustaining operations, while valuation is rated 1/10, signaling extreme overpricing relative to historical benchmarks.

Profitability and momentum both score 3/10, highlighting that the business is not yet generating sufficient earnings or positive short-term price acceleration to justify the current multiple. The reliance on price-to-sales analysis underscores the risk, as the margin of safety has eroded significantly compared to the company's historical valuation levels.

Insiders sold $11.4 million in shares

Corporate insiders have divested $11.4 million worth of TXG stock over the past 12 months, with no corresponding buying activity recorded. This net selling behavior suggests that those with the deepest knowledge of the company's operations are reducing their exposure during the current rally. The absence of insider accumulation contrasts with the broader market enthusiasm driving the 425% annual gain.

Mixed sentiment among professional investors

Nine gurus currently hold positions in 10x Genomics, but their actions are divided. Three have added to their stakes in recent quarters, while six have trimmed their holdings. This split indicates divergent views on the company's long-term trajectory, with some investors betting on the strength of its financial position and others retreating due to the inflated valuation. The combined effect of insider selling and mixed guru activity creates a cautious backdrop for the stock's continued appreciation.